Experiences with administration of Gesavit 50

MUDr. Martin Novák

Gastroenterology Clinic, City Hospital Čáslav

Address: 286 01 Čáslav, Jeníkovská 348, phone: 327305243

 

Study period:

6/2011-9/2011

 

Patient group:

5 patients in total were included with ulcerative disease of duodenum and gastric antrum.

Age range:

45-75 years,

3 women, 2 men

Initial assessment:

Gastroscopy results - 3x duodenal ulcers, lx ulcer of pyloric canal, lx ulcer of gastric antrum

Follow-up assessment::

Gastroscopy results: 4x completely healed ulcers, lx reduction of antrum ulcer size Laboratory tests:

were performed in three patients. A single one-off test was done during the therapy provided. The tests showed no increase in liver test values, renal function or blood count changes.

Therapy:

Patients were given proton pump inhibitors – PPIs (Helicid, Lanzul Nolpaza) or H2-receptor antagonists (Quamatel). The usual dosage was recommended.

Gesavit 50 was recommended along with the therapy in a dose of 2x1 capsules daily. The length of therapy with Gesavit 50 was a minimum of 3 weeks.

 

Side effects while using Gesavit 50:

Patients showed no side effects during the therapy, no allergic reaction was noted. Patients were in a good condition throughout. No coincidence with infectious diseases occurred.

 

Conclusion:

The complementary therapy using Gesavit 50 was perceived as positive by patients. Therapy effects were clearly helped by the primary antisecretory therapy. No side effects occurred during the administration. The group of patients tested for Gesavit 50 is small, but the therapy outcomes for ulcerative diseases may be considered very promising.

 

in Čáslavi 3.10.2011

Mudr. Martin Novák
Gastroenterology Clinic, City Hospital Čáslav

 razitko Čáslav